Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 1801 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Parsons L. Novartis acquires The Medicines Company for $9.7bn following takeover rumours. PMLiVE 2019:25 de noviembre. [Ref.ID 103211]
2. Cita con resumen
Byrne P, Cullinan J, Smith S. Statins for primary prevention of cardiovascular disease. BMJ 2019;367:16 de octubre. [Ref.ID 103197]
3.Enlace a cita original Cita con resumen
Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. Eur J Clin Pharmacol 2019;75:1387-92. [Ref.ID 103185]
4.Enlace a cita original Cita con resumen
Bosch J, O'Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avezum A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Sliwa K, Lee SF, Pogue JM, Hart R, Yusuf S, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology 2019;92:26 de marzo. [Ref.ID 103120]
5. Cita con resumen
Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]
6.Enlace a cita original Cita con resumen
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]
7.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
8.Enlace a cita original Cita con resumen
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
10.Enlace a cita original Cita con resumen
Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102883]
11.Enlace a cita original Cita con resumen
Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
Samper E. Así influyen las farmacéuticas sobre los médicos . eldiario.es 2018:18 de octubre. [Ref.ID 102834]
13.Enlace a cita original Cita con resumen
Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018;74:1061-70. [Ref.ID 102823]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navarese EP, Robinson JG, Kowatewski M, Kotodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102784]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navar AM, Peterson ED. Challenges in interpreting the lipid-lowering trials: biology vs ecology. JAMA 2018;319:17 de abril. [Ref.ID 102783]
17.Enlace a cita original Cita con resumen
Voelker R. Another caution for clarithromycin. JAMA 2018;319:1 de junio. [Ref.ID 102782]
18.Enlace a cita original Cita con resumen
Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]
19.Enlace a cita original Cita con resumen
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9. [Ref.ID 102647]
20. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
Seleccionar todas
 
 1 a 20 de 1801 siguiente >>